Bausch Health Reports Revenue Growth Amid Widening Q1 Net Loss

Bausch Health Companies Inc. (BHC) has announced its financial results for the first quarter of 2026, revealing a period of strong top-line expansion contrasted by a sharp increase in reported net losses. The company's total consolidated revenues reached $2.52 billion, representing a 12% increase over the $2.26 billion reported in the same period last year. On an organic basis, revenue growth stood at 7%, marking the twelfth consecutive period of year-over-year growth. Despite the revenue momentum, the reported net loss for the quarter surged to $1.423 billion, or $3.82 per share, a significant decline from the $58 million loss recorded in the first quarter of 2025. However, the company's adjusted net income showed improvement, rising to $296 million, or $0.78 per share, compared to $220 million, or $0.59 per share, in the prior year. CEO Thomas J. Appio attributed the performance to strategic execution and disciplined accountability across the organization. The company continues to prioritize its research and development pipeline, specifically highlighting the advancement of larsucosterol, a treatment for alcohol-associated hepatitis, while seeking further business development opportunities. Looking ahead, Bausch Health has reaffirmed its full-year 2026 outlook. The company expects total annual revenues to fall within the range of $10.670 billion to $10.920 billion, signaling confidence in its current growth trajectory and sustainable performance.